Pfizer에 대한 매도 수량은 투자자에게 Pfizer의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Pfizer (NYSE:PFE) 주식, 공매도 수량 보고

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Biotech

News

Specialty ETFs

Health Care

Politics

ETFs

General

ABBV

AMGN

SCHD

슈왑 미국 배당주 ETF(NYSE:SCHD)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. SCHD 펀드가 하락한 이유를 살펴보자.

슈왑 미국 배당주 ETF(SCHD), 12월에 7% 이상 하락한 이유는?

Movers

처방약급여관리업체(PBM)인 CVS헬스(NYSE:CVS), 유나이티드헬스 그룹(NYSE:UNH), 시그나 그룹(NYSE:CI)의 주가는 화요일(17일)에도 계속 하락세를 보였다. 도널드 트럼프 대통령 당선인이 의약품 중개업체(middleman)를 업계에서 퇴출시키려는 계획에 대해 공격적인 발언을 한 이후 하락 입력이 지속되었다.

CVS헬스·시그나·유나이티드헬스 주가 지속 하락하는 이유는?

Technicals

Trading Ideas

Pfizer Inc. 주식이 급등하고 있습니다. 하지만 주가가 저항선에 부딪혔습니다.

주가는 곧 돌파할 가능성이 있습니다. 이는 새로운 상승 추세로 이어질 수 있습니다. 그래서 저희 트레이더 및 기술 분석가 팀이 이를 오늘의 주식으로 선정했습니다.

일부 애널리스트들은 회사의 가이던스 재확인이 주가 상승의 원인이라고 분석하고 있습니다. Pfizer는 연간 매출을 610억 달러에서 640억

오늘의 주식: 화이자가 저항선을 테스트 중, 돌파하면 새로운 상승추세가 예상

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

The Schwab US Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know">plaguing the fund. </a>
What To Know: The Schwab US Dividend Equity ETF is heavily weighted in the healthcare sector with four pharmaceutical stocks representing 15.83% of the fund's total holdings. The sector has underperformed recently as increased uncertainty emerged surrounding the potential appointments and <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">policy changes</a> that could come under President-elect Donald Trump.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/social-media/24/12/42598651/mystery-drone-sightings-all-over-the-country-trump-says-what-to-know-about-investigations-lawmakers-reactions">&#8216;Mystery Drone&#8217; Sightings Spark Investigations, Politicians Respond: &#8216;Shoot Them Down,&#8217; Trump Says</a>
<h2 class="wp-block-heading">Healthcare Holdings</h2>
Bristol-Meyers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) is the fund's top pharmaceutical holding, representing 4.64% of its assets. The stock is down 2.6% over the past month. 
Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is also in the fund's top 10 holdings. It fell more than 5% following the presidential election as the vaccine-maker faces an uncertain political and regulatory environment ahead. 
AbbVie, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Amgen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) round out the dividend-focused fund's healthcare holdings.  AbbVie shares are down slightly, though Amgen shares are down by more than 10% in December following disappointing <a href="https://www.benzinga.com/content/42377651/amgen-stock-falls-on-weight-loss-drug-data-overreaction-or-fair">clinical trial </a>results from its weight-loss drug candidate, MariTide. 
Interest Rates: Another factor that could be affecting the Schwab dividend-focused fund is the uncertain interest rate environment. Dividends tend to become more attractive to investors in a low-interest rate environment. Recent comments from the Federal Reserve suggest a more hawkish outlook with inflation remaining sticky and above the Fed's target rate of 2%.&nbsp;
Additionally, the incoming Trump administration could again play a factor as Trump has pledged to raise tariffs on foreign imports which could reignite inflation and lead to interest rates staying higher for longer.&nbsp;
When interest rates are high, the yields on bonds and other fixed-income securities become more competitive, making dividend yields less appealing by comparison.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42653466/honda-nissan-plan-to-merge-in-the-face-of-chinese-ev-competition">Honda, Nissan Confirm Merger Plans To Offset Chinese EV Competition: How Mitsubishi Factors In</a></li>
</ul>
Image: Shutterstock

Schwab US Dividend Equity ETF Reverses In December: What's Going On?

High-rolling investors have positioned themselves bullish on Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in PFE often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Pfizer. This is not a typical pattern.
The sentiment among these major traders is split, with 55% bullish and 44% bearish. Among all the options we identified, there was one put, amounting to $28,350, and 8 calls, totaling $607,915.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $27.5 for Pfizer over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $15.0 to $27.5 over the preceding 30 days.
<h3>Pfizer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734978633_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.77</td>
<td>$0.74</td>
<td>$0.77</td>
<td>$27.00</td>
<td>$226.0K</td>
<td>18.6K</td>
<td>3.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$22.00</td>
<td>$96.9K</td>
<td>4</td>
<td>300</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.5</td>
<td>$6.4</td>
<td>$6.47</td>
<td>$20.00</td>
<td>$64.7K</td>
<td>3.5K</td>
<td>100</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$11.55</td>
<td>$11.2</td>
<td>$11.43</td>
<td>$15.00</td>
<td>$57.1K</td>
<td>338</td>
<td>50</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.67</td>
<td>$1.64</td>
<td>$1.67</td>
<td>$25.00</td>
<td>$49.9K</td>
<td>44.0K</td>
<td>372</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
After a thorough review of the options trading surrounding Pfizer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Pfizer</h3>
<ul>
<li>Currently trading with a volume of 15,591,857, the PFE's price is up by 0.74%, now at $26.55. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 43 days.</li>
</ul>
<h3>Expert Opinions on Pfizer</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $31.333333333333332.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from B of A Securities lowers its rating to Neutral with a new price target of $29. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Pfizer, which currently sits at a price target of $33. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Pfizer with a target price of $32. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

This Is What Whales Are Betting On Pfizer

Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items &#8211; a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.
Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Pfizer, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/PFE/analyst-ratings" rel="noreferrer noopener">price target of $33</a>.
Shibutani recalled that Pfizer had reported negative results from a Phase 3 study for a first-generation asset in March 2022, where the primary endpoint was unmet.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42645821/elon-musks-xai-expands-with-new-chatbot-app" rel="noreferrer noopener">Elon Musk&#8217;s xAI To Expand With New Chatbot App</a>
Still, results did include signals from secondary endpoints that suggested reduced disease severity.
Pfizer has since been exploring updated formulations (reducing the 3-dose regimen to 2 doses), including a version in Phase 2. Immunogenicity data are anticipated in 2025, with potential for advancement into Phase 3 by the end of 2025.
For a potential Phase 3 study, Shibutani noted the objective would be to discern the potential to reduce the severity of a C. diff infection (CDI) instead of aiming to reduce the risk and prevention of disease.
Pfizer estimates ~500k infections annually in the U.S., and no vaccine options currently available. Acknowledging that there is an unmet need The analyst acknowledged that there is an unmet need and said the data thus far suggests a potential basis for a path forward for the program in the context of comments from R&amp;D leadership during the discussion Shibutani hosted with investors.
The emphasis on the forward will be on programs with the most significant potential for economic returns. The analyst expects that investor enthusiasm will likely remain relatively subdued, especially in the context of uncertainties deriving from health policy dynamics relating to vaccines, that are an overhang to sentiment.
Shibutani does not currently include revenue estimates for a C. diff vaccine in his model and looks to monitor data updates and decisions regarding plans for this program to guide his forecasts in the future.
Separately, the analyst flagged Pfizer management&#8217;s mention of the fourth generation 25-valent pneumococcal vaccine (PCV), which management affirms continues to progress in Phase 2.
Shibutani recalled that Pfizer had previously commented that the immunogenicity data from Phase 1 were encouraging, as highlighted by the improved immunogenicity observed for serotype 3.
Pfizer is currently in a Phase 2 proof-of-concept study for its second-generation Clostridioides difficile (C. diff) vaccine, PF-07831694. This vaccine targets C. diff toxins A and B, which cause Clostridioides difficile infection (CDI).&nbsp;&nbsp;
Their goal for the second generation is to build off the 1st generation&#8217;s efficacy and duration by developing a more potent, more durable formulation, allowing for a 2-dose regiment (instead of 3-dose), resulting in higher and faster series completion.
After evaluating adjuvants in formulation for their next-generation candidates, Pfizer noted they can increase the strength or magnitude of the immune response, potentially resulting in lower doses.
Pfizer advanced 1 of the three updated 2nd-generation candidates to Phase 2 based on Phase 1/2 safety and immunogenicity data.
The Phase 2 trial endpoints will evaluate the immunogenicity and safety of the 2-dose regimen. Trial data is expected in 2025, with a potential Phase 3 start in late 2025, pending positive results.
Pfizer in Phase 2 is the furthest along of the C. diff vaccine assets. Idorsia Pharmaceuticals initiated Phase 1 for their competing C. diff asset in July. Vaxxilon and Matrivax Research &amp; Development Corporation both have preclinical assets. GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) CDI vaccine completed a Phase 1 trial in 2022 but is no longer listed as a pipeline asset.&nbsp;&nbsp;
Pfizer&nbsp;stock has dropped over 11.5% year-to-date. Investors can gain exposure to the stock through SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>).
Price Action: PFE stock is up 0.82% at $26.58 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42644888/biden-administration-targets-chinese-firm-over-taiwan-semiconductor-chip-found-in-huawei-tech" target="_blank" rel="noreferrer noopener">Biden Administration Targets Chinese Firm Over Taiwan Semiconductor Chip Found in Huawei Tech</a></li>
</ul>
Photo via Shutterstock

Price Target

Reiteration

Analyst Ratings

Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf</a>
On December 20, 2024, the Food and Drug Administration granted accelerated approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Full prescribing information for Braftovi will be posted on <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm">Drugs@FDA</a>. &nbsp;
<h2>Efficacy and Safety</h2>
Efficacy was evaluated in BREAKWATER (NCT04607421), an active-controlled, open-label, multicenter trial. Patients were required to have treatment naïve BRAF V600E mutation-positive mCRC, detected by the Qiagen therascreen BRAF V600E RGQ polymerase chain reaction kit. Patients were initially randomized 1:1:1 to one of the following treatment arms:
<ul>
<li>encorafenib orally once daily with cetuximab IV infusion every 2 weeks (encorafenib+cetuximab arm),&nbsp;</li>
<li>encorafenib orally once daily with cetuximab IV infusion every 2 weeks and mFOLFOX6 every 2 weeks (encorafenib+cetuximab+mFOLFOX6 arm), or</li>
<li>mFOLFOX6, FOLFOXIRI (both every 2 weeks) or CAPOX (every 3 weeks)-each with or without bevacizumab (control arm).</li>
</ul>
The trial was subsequently amended to limit randomization (1:1) to the encorafenib +cetuximab+mFOLFOX6 arm and the control arm. Treatment in all arms continued until disease progression, unacceptable toxicity, consent withdrawal, lost to follow-up, or death. The results of the encorafenib + cetuximab + mFOLFOX6 arm compared to the control arm served as the basis of this accelerated approval and are described below.
The major efficacy outcome measure was confirmed objective response rate (ORR) assessed by blinded independent central review and evaluated in the first 110 patients randomized in each arm. ORR was 61% (95% CI: 52%, 70%) in the encorafenib+ cetuximab, + mFOLFOX6 arm and 40% (95% CI: 31%, 49%) in the control arm. Median DoR was 13.9 months (95% CI: 8.5, not estimable) and 11.1 months (95% CI: 6.7, 12.7) in the respective arms.
Evaluation of progression-free survival and overall survival in the ongoing BREAKWATER trial will serve as post-marketing confirmatory evidence for this accelerated approval. This application is an example of the Oncology Center of Excellence's Project FrontRunner aimed at moving important therapies to earlier disease settings.
The most common adverse reactions (≥25%) were peripheral neuropathy, nausea, fatigue, rash, diarrhea, decreased appetite, vomiting, hemorrhage, abdominal pain, and pyrexia. The most common Grade 3 or 4 laboratory abnormalities (≥20%) were increased lipase and decreased neutrophil count.
The recommended encorafenib dose is 300 mg (four 75 mg capsules) orally once daily in combination with cetuximab and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) until disease progression or unacceptable toxicity. Full dosing information is provided in the prescribing information.
This review was conducted under <a href="https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis">Project Orbis</a>, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with Health Canada. The application review is ongoing at the other regulatory agencies.

FDA Grants Accelerated Approval To Encorafenib With Cetuximab And mFOLFOX6 For Metastatic Colorectal Cancer With A BRAF V600E Mutation

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Government

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

DARE

ENDPQ

TEVA

U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood

Truist Securities analyst Robyn Karnauskas maintains Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Buy and lowers the price target from $36 to $32.

Truist Securities Maintains Buy on Pfizer, Lowers Price Target to $32

Shares of Pharmacy-benefit managers (PBMs) including&nbsp;CVS Health Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>),&nbsp;UnitedHealth Group Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and Cigna Group&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) are moving lower Tuesday on continued downside pressure following aggressive commentary from President-elect&nbsp;Donald Trump&nbsp;regarding plans to cut <a href="https://www.benzinga.com/24/12/42517567/cvs-cigna-unitedhealth-shares-slide-as-trump-targets-drug-middleman">drug middlemen out of the industry</a>.
What To Know: Trump on Monday announced plans to "knock out" PBMs, or so-called drug middlemen, from the healthcare industry, according to <a href="https://www.bloomberg.com/news/articles/2024-12-16/trump-middleman-remark-sinks-cvs-unitedhealth-cigna-shares?srnd=homepage-americas&amp;sref=TBDibEcD">Bloomberg</a>. 
&#8220;You know the middleman, right? The horrible middleman that makes more money frankly than the drug companies, and they don&#8217;t do anything except they&#8217;re a middleman,&#8221; President-elect Trump said. &#8220;We&#8217;re going to knock out the middleman.&#8221;
CVS Health's Caremark,&nbsp;UnitedHealth's OptumRx and Cigna's Express Scripts are the three largest PBMs. The companies have faced repeated criticism for driving up the prices of drugs. The role of PBMs in the industry has seen increased attention in recent weeks following the murder&nbsp;of&nbsp;<a href="https://www.benzinga.com/general/restaurants/24/12/42427146/pennsylvania-mcdonalds-where-unitedhealthcare-ceo-murder-suspect-arrested-gets-review-bombed-more-like-narc-donalds">UnitedHealthcare&nbsp;CEO&nbsp;Brian Thompson</a>.
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/health-care/24/12/42371469/blue-shields-500-million-drug-savings-initiative-with-amazon-pharmacy-can-potentially-launch-in-january">Blue Shield&#8217;s $500 Million Drug Savings Initiative With Amazon Pharmacy Can Potentially Launch In January</a>
Shares of CVS, UnitedHealth and Cigna all traded lower on Monday following Trump&#8217;s comments. The trio is moving lower again on Tuesday after Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla said Trump is &#8220;very committed&#8221; to implementing changes to stop drug middlemen from inflating prices. 
&#8220;The president has very strong views,&#8221; Bourla said on a call with analysts and investors Tuesday morning, before adding that Trump &#8220;wants transparency.&#8221;
"It seems to me that he is very committed to make this happen," the Pfizer CEO said.
Sen.&nbsp;Elizabeth Warren&nbsp;(D.-Mass.) and&nbsp;Sen. Josh Hawley&nbsp;(R.-Mo.) unveiled a <a href="https://www.benzinga.com/general/health-care/24/12/42450947/bipartisan-lawmakers-aim-to-break-up-health-care-giants-with-new-legislation">new Senate bill</a> last week that would require the companies that own PBMs to divest those businesses within three years.
The proposed legislation is not expected to gain traction in Congress until next year. 
CVS, UNH CI Price Action: At the time of publication, CVS shares were down 5.48% at $44.01, UnitedHealth shares were down 2.66% at $485.15 and Cigna shares were down 2.84% at $265.54, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

What's Going On With CVS Health, UnitedHealth And Cigna Group Shares?

Macro Economic Events

Market Summary

Economics

Benzinga Market Summary: S&P Falls, Pfizer Rises On 2025 Outlook, Healthcare And Chip Stocks Decline

Shares of Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) are making a large move higher Tuesday. But the stock <a href="https://www.benzinga.com/general/biotech/24/12/42530634/pfizer-does-not-anticipate-material-changes-to-us-vaccine-policy-from-the-incoming-administration-in-2025">has run into resistance</a>.
It may be about to break out. This could be followed by a new uptrend. This is why our team of traders and technical analysts has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
Some analysts are attributing the move to the <a href="https://www.benzinga.com/general/biotech/24/12/42530634/pfizer-does-not-anticipate-material-changes-to-us-vaccine-policy-from-the-incoming-administration-in-2025">company's reaffirmation of its guidance</a>. Pfizer sees annual sales between $61 billion and $64 billion. It also sees earnings of between $2.75 and $2.95 per share. Both numbers are in line with estimates.
As you can see on the chart, the stock is testing resistance around $26.30. If this resistance ‘breaks', there is a good chance a new uptrend forms.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17120556/13-1024x559.png" alt="Pfizer" class="wp-image-696182" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17120556/13-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17120556/13-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17120556/13-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17120556/13.png 1491w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
When a stock is trending higher, there isn't enough supply to fill all the demand. There are more buy orders than there are sell orders.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42526592/bitcoin-ethereum-etfs-see-688m-net-inflows-analysts-target-124000">Bitcoin, Ethereum ETFs See $688M Net Inflows, Analysts Target $124,000</a>
To get sellers interested, buyers must be willing to pay successively higher prices. This forces the shares into an uptrend.
At a resistance level, the tide turns. Resistance is a large concentration of investors and traders who are looking to sell at, or close to, the same price.
At resistance levels, there is enough supply to satisfy all the demand. Traders can buy all they wish to without pushing the price up.
This is why rallies end or pause when they reach resistance.
If the price can get and stay above a resistance level, traders say that it has staged a ‘breakout'. This illustrates an important market dynamic.
It means that the people who created the resistance with their sell orders are gone. They have either canceled or finished their orders.
With this large amount of supply taken out of the market, buyers may be once again forced to pay premiums to get the interest of sellers. This could create a new uptrend for Pfizer.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42531373/financial-stocks-near-record-year-could-trump-deregulation-fuel-bigger-gains-in-2025">Financial Stocks Near Record Year: Could Trump Deregulation Fuel Bigger Gains In 2025?</a></li>
</ul>
Image: Shutterstock

Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks

Wall Street began Tuesday&#8217;s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back interest <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">rate cuts next year. </a>
The data, which underscored resilient consumer spending heading into the holiday season, added a fresh layer of uncertainty to the Fed's future rate path ahead of Wednesday&#8217;s highly awaited December Federal Open Market Committee meeting.
Retail sales surged 0.7% last month, outperforming consensus estimates of a 0.5% increase and marking a notable acceleration from October's <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42529956/november-retail-sales-soar-to-11-month-highs-indicate-strong-holiday-season">upwardly revised 0.5% gain. </a>
On an annual basis, sales climbed 3.8%, hitting their fastest pace since December 2023. A significant portion of the strength came from auto sales, which soared 2.6% on a monthly basis and by a robust 6.5% year-over-year, highlighting consumers' willingness to make big-ticket purchases in the fourth quarter of the year.
Spending was also robust in other categories. Nonstore retailers, driven by e-commerce activity, posted a 1.8% monthly gain, reflecting the growing dominance of online shopping as the holiday season commenced. Sporting goods, hobby, and book stores registered a 0.9% uptick, showing steady demand for discretionary items.
<h3 class="wp-block-heading">Market Reaction: Pressure Builds On Equities</h3>
The stronger-than-expected data put equity markets under pressure, as investors recalibrated their expectations for the Fed's next moves. 
The S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – and Dow Jones Industrial Average both fell 0.7%, while the Nasdaq 100 – tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – slid 0.8%, weighed down by weakness in the chip sector. 
Semiconductor stocks led the downturn amid renewed geopolitical tensions after reports surfaced that China is broadening antitrust scrutiny on U.S. chipmakers&#8217; acquisitions in recent years. Last week, Beijing opened an investigation on U.S. chip giant Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 2019 acquisition of Mellanox Technologies.
<h3 class="wp-block-heading">Investors Face Fed Uncertainty</h3>
The robust retail sales data is the latest in a series of reports—alongside <a href="https://www.benzinga.com/news/treasuries/24/12/42460477/producer-inflation-rises-more-than-expected-to-3-in-november-cast-shadow-on-further-disinflation-progress">hotter-than-expected inflation prints</a> and upbeat <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42511277/us-services-sector-booms-at-fastest-pace-since-october-2021-business-activity-leaps-to-over-two-year-highs">December Purchasing Managers&#8217; Index surveys</a>—that challenge the case for aggressive rate cuts next year.
While a 25-basis-point reduction at the Fed's policy meeting this week is widely anticipated, the central bank's outlook for 2025 remains in question.
Fed fund futures now suggest an 80% chance the Fed will hold rates steady at its January meeting, while expectations for a March rate cut have softened, with odds slipping to 58% from 60% a day earlier.
Betting-implied odds from CFTC-regulated Kalshi continue to suggest an elevated 92% probability of four cuts next year, yet financial markets now imply only three rate cuts. 
<h3 class="wp-block-heading">Top 5 S&amp;P 500 Performers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Price ($)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>SolarEdge Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>)</td>
<td>14.35</td>
<td>+16.57%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>26.24</td>
<td>+3.88%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>68.65</td>
<td>+3.26%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>475.11</td>
<td>+2.82%</td>
</tr>
<tr>
<td>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>42.81</td>
<td>+2.37%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top 5 S&amp;P 500 Losers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Price ($)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>234.36</td>
<td>-6.29%</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>21.00</td>
<td>-4.35%</td>
</tr>
<tr>
<td>Constellation Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>231.09</td>
<td>-3.43%</td>
</tr>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>252.18</td>
<td>-3.33%</td>
</tr>
<tr>
<td>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</td>
<td>91.18</td>
<td>-3.25%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top 5 Nasdaq 100 Performers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Price ($)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Super Micro Computer Inc. (NASDAQ: SMCI9 </td>
<td>34.47</td>
<td>+3.08%</td>
</tr>
<tr>
<td>Tesla Inc.</td>
<td>472.84</td>
<td>+2.33%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>)</td>
<td>740.51</td>
<td>+2.24%</td>
</tr>
<tr>
<td>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)</td>
<td>738.86</td>
<td>+2.22%</td>
</tr>
<tr>
<td>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXP#NASDAQ">NXP</a>)</td>
<td>222.95</td>
<td>+2.21%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top 5 Nasdaq 100 Losers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Price ($)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>)</td>
<td>114.10</td>
<td>-8.52%</td>
</tr>
<tr>
<td>Broadcom</td>
<td>234.15</td>
<td>-6.37%</td>
</tr>
<tr>
<td>Nvidia</td>
<td>127.15</td>
<td>-3.65%</td>
</tr>
<tr>
<td>Constellation Energy</td>
<td>231.04</td>
<td>-3.45%</td>
</tr>
<tr>
<td>SiriusXM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)</td>
<td>22.02</td>
<td>-2.76%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42531373/financial-stocks-near-record-year-could-trump-deregulation-fuel-bigger-gains-in-2025">Financial Stocks Near Record Year: Could Trump Deregulation Fuel Bigger Gains In 2025?</a></li>
</ul>
Image created using photos from Shutterstock.

Equities

Broad U.S. Equity ETFs

Retail Sales

Econ #s

Federal Reserve

ASML

AVGO

MRNA

MRVL

NVDA

REGN

SEDG

SIRI

TSLA

Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts

Pfizer CFO Does Not Expect Large Deals In 2025, Says Those Will Be A Focus In 2026 And Beyond; CEO Says "Developed A Good Relationship" With HHS Nominee Kennedy During Dinner With Trump; CEO Says Expecting A New Wave Of Covid Exiting 2024 And Entering 2025

On Tuesday, Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42515106/what-to-expect-when-pfizer-outlines-its-2025-financial-outlook-on-tuesday" rel="noreferrer noopener">consensus of $63.28 billion</a>.
For 2025, Pfizer expects revenue from COVID-19 products to remain consistent with 2024, excluding approximately $1.2 billion in one-time Paxlovid <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42526212/pfizer-provides-full-year-2025-guidance-and-reaffirms-full-year-2024-guidance" rel="noreferrer noopener">revenue recognized in 2024</a>.
The guidance accounts for an estimated $1 billion net unfavorable revenue impact due to changes under the Inflation Reduction Act (IRA), particularly Medicare Part D redesign.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42299374/pfizers-new-chief-scientific-officer-charts-strategic-rd-vision-highlights-balanced-approach-to-high-and-low-risk-investments" rel="noreferrer noopener">Pfizer&#8217;s New Chief Scientific Officer Charts R&amp;D Vision For High And Low-Risk Investments</a>
While IRA provisions like the $2,000 annual out-of-pocket cap are expected to benefit revenues, these are offset by eliminating the Coverage Gap Discount Program and adding manufacturer discounts in certain coverage phases.
The company projects operational revenue growth of flat to 5% year-over-year from the midpoint of 2024 baseline guidance, excluding non-recurring items.
On expenses, Pfizer anticipates full-year 2025 adjusted Selling, Informational, and Administrative expenses of $13.3 billion and $14.3 billion, while adjusted R&amp;D expenses are expected between $10.7 billion and $11.7 billion.
Pfizer estimates total adjusted SI&amp;A and R&amp;D expenses to fall between $24.0 billion and $26.0 billion, reflecting $4.0 billion in savings from its cost realignment program by the end of 2024 and an additional $500 million in savings expected in 2025.
For adjusted EPS, Pfizer projects $2.80 to $3.00 in 2025, reflecting anticipated operational growth of 10% to 18% year-over-year from the midpoint of 2024 baseline guidance.
The expected improvement is attributed to higher revenues, improved operating margins driven by ongoing cost management, and the non-recurrence of one-time items that boosted 2024 adjusted EPS by approximately $0.30.
These items included $1.2 billion in Paxlovid revenue and the removal of Haleon equity method income following the reduction of Pfizer&#8217;s ownership stake in the fourth quarter of 2024.
The company also reaffirmed its 2024 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">full-year 2024 guidance</a>.
Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, stated: &#8220;Pfizer is in a strong position to continue making a positive impact for patients and delivering on our financial commitments in 2025.&#8221;
He added, &#8220;We also expect to continue improving our operating margins with focused financial discipline. We&#8217;ve been successful in delivering on our goal of $4 billion in net operating expense savings through 2024 from our cost realignment program, with an additional $500 million still expected to come in 2025. Additionally, in support of our ongoing efforts to improve gross margin performance, we will work to make additional progress with our Manufacturing Optimization Program in the coming year.&#8221;
On the conference call, the company said it does not expect material U.S. policy changes regarding vaccines from the incoming administration in 2025.
Price Action: At last check on Tuesday, PFE stock was up 2.46% to $25.87 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514620/googles-veo-2-and-imagen-3-set-new-standards-for-ai-creativity" target="_blank" rel="noreferrer noopener">Google&#8217;s Sora Rival &#8211; DeepMind Introduces New Video Generation Tool</a></li>
</ul>
Photo via Company

Earnings

Large Cap

Guidance

Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025

Pfizer Expects No Material US Policy Changes Regarding Vaccines From  Incoming Administration In 2025

WIIM

Pfizer shares are trading higher after the company issued its 2025 outlook.

Pfizer Reaffirms FY24 Outlook For Revenue Of $61B – $64B (Est $62.974B), Adj EPS Of $2.75 – $2.95 (Est $2.92)

Pfizer Says First Phase Of Manufacturing Optimization Program On Track To Deliver Initial Net Cost Savings In The Latter Part Of 2025

Pfizer Says It Achieved Goal Of $4B In Net Cost Savings Through 2024; Anticipates Additional $500M In Savings In 2025 From Ongoing Cost Realignment Program

Pfizer Expects FY25 Revenue Of $61B - $64B  (Est $63.276B), Adjusted EPS Of $2.80 - $3.00 (Est $2.90)

Pfizer Provides Its Full-year 2025 Guidance And Reaffirms Its Full-year 2024 Guidance

Impax Global Social Leaders Fund Q3 2024 Commentary

Pfizer (PFE) announced that the Food and Drug Administration has approved Braftovi in combination with cetuximab and mFOLFOX6 for the treatment of ...

Pfizer announces FDA approval of Braftovi combination

Pfizer gets FDA accelerated approval for Braftovi

Hartford Balanced Income Fund Q3 2024 Commentary

Pfizer Inc. recently released its full-year 2025 guidance and reaffirmed its 2024 outlook, aligning with Street expectations. It seems having faith in the company may have paid off.

Pfizer: Guidance Reaffirmed, Nice Yield. What's Not To Like?

SA Asks: Which Big Pharmas are likely to announce big M&A deals?

In a report released yesterday, Steve Scala from TD Cowen maintained a Hold rating on Pfizer (PFE – Research Report). The company's shares closed l...

TD Cowen Sticks to Its Hold Rating for Pfizer (PFE)

Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked

Pfizer stock ($PFE) has had a rough ride over the past year, declining by around 7% and underperforming the broader market by a wide margin. This s...

Pfizer ($PFE) Stock Has Evolved Into a Solid Income Play

Hartford Equity Income Fund Q3 2024 Commentary

BIIB

CRSP

CSCO

DUOL

EBAY

GILD

HLNCF

HSRT

INTU

ISRG

KRYAF

KRYAY

MBLY

MELI

NONOF

ORCL

VRTX

WOLTF

WTKWY

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-11-13 at 11.54.41 PM

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

Pfizer Declares First-Quarter 2025 Dividend

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

Roam For the Holidays: Grindr Offers Free Access to Their Popular Travel Feature

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

Stuart Therapeutics Announces the Appointment of Two New Board Members

ARVN

GRND

ONCY

TSX:ONC

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Pfizer

매도 수량

Pfizer (NYSE:PFE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌